Symptoms and General Pathology

All Conditions

Neoplasms

Ear, Nose, and Throat Diseases

Nervous System Diseases

Rare Diseases

Edema

Neoplasm Metastasis

Neurilemmoma

Vertigo

Dizziness

Dilatation, Pathologic

Neuroma, Acoustic

Endolymphatic Hydrops

Neuroma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Nerve Sheath Neoplasms

Neoplasms, Nerve Tissue

Nervous System Neoplasms

Peripheral Nervous System Neoplasms

Vestibulocochlear Nerve Diseases

Retrocochlear Diseases

Ear Diseases

Otorhinolaryngologic Diseases

Otorhinolaryngologic Neoplasms

Cranial Nerve Diseases

Labyrinth Diseases

Labyrinthitis

Schwannoma

Acoustic Neuroma

Neuroendocrine Tumor

Neuroepithelioma

Aïna VENKATASAMY,, MD

Aurélie KARCH-GEORGES, MD

Aïna VENKATASAMY, MD

Francis VEILLON, MD, PhD

Endolymphatic hydrops is well known of the lay public in its primary form that is Ménière disease. Nowadays, the best w ay to approach it in vivo, is to use magnetic resonance imaging (MRI).

However, endolymphatic hydrops don't limit itself to its primary form but cover a whole range of pathologies.

The hypothesis is that patients with vestibular schwannomas are more likely to develop secondary saccular hydrops.

The aim is to compare high-resolution T2-weighted images of the saccule in patients followed up for vestibular schwannomas with healthy volunteers and histological sections from cadavers in order to identify its changes.

The secondary purpose of The protocol is to determine if vestibular and audiometric abnormalities could be related to this secondary hydrops more specifically than to the tumor size and localisation.

Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI

Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI

University Hospital, Strasbourg, France

Skin and Connective Tissue Diseases

Ganglion Cysts

Hearing Loss

Deafness

Synovial Cyst

Meniere Disease

Cysts

Mucinoses

Connective Tissue Diseases

Vestibular Diseases

Neurologic Manifestations

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

All Drugs and Chemicals

Antiemetics

Gastrointestinal Agents

Hematinics

Vitamins

Niacin

Nicotinic Acids

Tocopherols

Vitamin E

Tocotrienols

alpha-Tocopherol

Diphenidol

Niacinamide

Antioxidants

Protective Agents

Trace Elements

Hypolipidemic Agents

Antimetabolites

Folic Acid

Vitamin B Complex

Nicotinic Acid

Vitamin B3

Tocopherol

Tocotrienol

Nicotinamide

Folate

Vitamin B9

treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).

stellate ganglion block

0.25mg of erispan@ (fludiazine), p.o. one dose only.

0.25mg, fludiazine

25mg cephadol@ (diphenidol) p.o. one dose only.

25mg cephadol@ (diphenidol)

200mg kentons@ (tocopherol nicotinate) p.o. one dose only.

200mg kentons@ (tocopherol nicotinate).

Yung-Song Lin, M.D.

Stellate ganglion block (SGB) has been the alternative treatment of Meniere's disease for years. However, objective evidence of the effect of SGB was still lack. The investigators conducted a randomized controlled study to examine the immediate effects of SGB in SP/AP of electrocochleography (ECoG).

Ten patients were randomly assigned to receive stellate ganglion block. These ten patients made up the experimental group. Another ten patients in the control group were assigned to receiving one dosage of oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).

Effect of Stellate Ganglion Block on Meniere's Disease

SP/AP of ECoG was recorded 2 hours after SGB. to be compared with the SP/AP of ECoG recorded before treatment

SP/AP recorded at 4 hours after SGB was compared with that of pretreatment with SGB

SP/AP recorded at 4 hours after SGB was compared with the SP/AP recorded before SGB

scores of verbal scale for vertigo recorded at 6 hours after SGB was compared to the scores recorded before SGB

Chi Mei Medical Hospital

Chairman of department of Otolaryngology

Digestive System Diseases

Sarcopenia

Peripheral Nervous System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Muscular Atrophy

Atrophy

Neuromuscular Manifestations

Pathological Conditions, Anatomical

Neuromuscular Diseases

Sensation Disorders

Patients in the intervention groups will receive neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions

Patients in the usual care groups will receive standard treatment with neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner

Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions

Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement

Katrine S Piper, PhD-Student

Jan Christensen, PhD

Cecilia M Lund, PhD

The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times/week can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy

Frequent adverse effects of chemotherapy in older adults are nausea and fatigue, but our research group have discovered a problem with many also suffering from sarcopenia, vertigo, dizziness, and peripheral neuropathy (CIPN) leading to balance and walking impairments causing increased risk of falls. Moreover, these symptoms are often underreported with inadequate awareness among health professionals leading to deficient focus on the need for targeted rehabilitation. A comprehensive geriatric assessment (CGA) can increase the number of frail, older patients completing chemotherapy and CGA-based interventions can decrease chemotherapy toxicity and improve health-related quality of life (HRQoL). Physical exercise has been shown to reduce muscle weakness, vertigo, dizziness, and impaired balance among older adults requiring limited resources. Therefore, this project aims to investigate the effectiveness of CGA and physical exercise to counteract muscle weakness, vertigo, instability, and impaired walking balance, during chemotherapy and to investigate the interaction between vertigo, postural stability and walking performance, and neuropathy and the prevalence of sarcopenia. The activities of specialized physical exercise planned in this intervention will, as hypothesized, result in a change in muscle strength, walking balance, self-perceived balance disabilities/dizziness, and fear of falling along with changes in peripheral nerve function and autonomic function and severity of CIPN which are the outcomes of this study. Accordingly, expectations are that this intervention will affect the HRQoL among older cancer patients with vertigo and walking impairments and reduce the number of falls and hospital admissions leading to a socioeconomic benefit.

The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer

Changes in walking speed using 10 meter walk test measuring gaitspeed in meters per second

Changes in postural control (standing balance) using HUR SmartBalance platform

Changes in peripheral vestibular function using Video Head Impulse Test (vHIT)

Changes in orthostatic blood pressure measured from lying to standing and every minute for five minutes

Changes in body composition using bioimpedance (BIA)

Changes in muscle quality using ultrasound

Presence of frailty using Geriatric-8 (G8) scored on a 0-17 point scale. Higher score means better outcome

Presence of frailty using Clinical Frailty Scale (CFS) scored on a 1-9 point scale. Higher score means worse outcome

Description of activity level using activity tracker

Recording of exercise through a prescribed rehabilitation plan

Biomarkers of sarcopenia and inflammation collected through blood samples. To determine concentration of inflammatory cytokines; High-sensitivity C-reactive Protein (hsCRP), tumour necrosis factor alpha (TNF- α), interleukin 6 (IL6), interleukin 13 (IL-13), and of muscle atrophy and muscle wasting (growth differentiation factor 11 (GDF11), and growth differentiation factor 15 (GDF-15). Blood samples are analysed by standard ELISA-analyses for plasma samples.

Measurement of vision using a Snellen chart

Between-group difference in change in walking balance assessed with Dynamic Gait Index (DGI) scored on a 0-24 point total scale. Higher score means better outcome

Between-group difference in lower limb muscle strength and endurance

Changes in self-perceived balance disabilities/dizziness using the patient reported outcome measure Dizziness Handicap Inventory (DHI) scored on a 0-100 point total scale. Higher score means worse outcome

Changes in fear of falling using the patient reported outcome measure Short Falls Efficacy Scale International (Short FES-I) scored on a 0-28 point total scale. Higher score means worse outcome

Changes in health related quality of life using the patient reported outcome measure EORTC QLQ-C30. The total score is converted to a 0-100 scale. Higher score means better outcome

Changes in peripheral nerve function using biothesiometer mesured in 0-50 volts. Higher volts means worse outcome

Changes in autonomic function using Vagus device

Severity of chemotherapy induced peripheral neuropathy using the patient reported outcome measure EORTC QLQ-CIPN-20. The total score is converted to a 0-100 scale. Higher score means worse outcome

Changes in muscle strength using HUR Leg Press Rehab performance recorder measuring weight in kilograms

Changes in muscle strength using handgrip test measuring weight in kilograms

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI	NCT03593577	Vestibular Schw...		18 Years -	University Hospital, Strasbourg, France
Effect of Stellate Ganglion Block on Meniere's Disease	NCT01574313	Vertigo Meniere Disease	stellate gangli... 0.25mg, fludiaz... 25mg cephadol@ ... 200mg kentons@ ...	30 Years - 65 Years	Chi Mei Medical Hospital
The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer	NCT05710809	Colorectal Canc... Oncologic Compl... Comprehensive G... Vestibular Reha... Geriatric Oncol... Sarcopenia Vertigo Cancer Rehabilitation Exercise Geriatric Elderly Frail Older Adults Chemotherapy Chemotherapy-in... Resistance Trai... Balance Trainin... Postural Stabil... Pragmatic Trial Personal Medici... Individualised	Targeted specia...	65 Years -	Rigshospitalet, Denmark
Effect of Stellate Ganglion Block on Meniere's Disease	NCT01574313	Vertigo Meniere Disease	stellate gangli... 0.25mg, fludiaz... 25mg cephadol@ ... 200mg kentons@ ...	30 Years - 65 Years	Chi Mei Medical Hospital

Spots Global Cancer Trial Database for vertigo

Every month we try and update this database with for vertigo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for vertigo

Every month we try and update this database with for vertigo cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for vertigo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.